Estimated carbon emissions for PBS‐subsidised prescription respiratory inhalers, Australia, 2019–2023: a descriptive analysis

The Australian National Health and Climate Strategy1 identifies reducing the use of pressurised, metered dose inhalers as a high priority for decarbonising health care. These high emissions inhalers contain potent greenhouse gases as propellants, producing ten to thirty times as much in carbon dioxide equivalent (CO₂e) emissions as low emissions inhalers (dry powder and soft mist inhalers), which are often clinically equivalent.

To investigate the carbon footprint of inhalers dispensed in Australia and subsidised by the Pharmaceutical Benefits Scheme (PBS), we analysed aggregate‐level PBS dispensing data for the period 1 January 2019 – 30 November 2023, based on United Kingdom estimates of emissions per inhaler.2 We aggregated the estimated emissions for all inhalers dispensed by year and type, and summarised age‐standardised population rates of inhaler dispensing. We then conducted time series analyses of monthly values, adjusted for autocorrelation, to derive regression trend lines; we estimated mean monthly percentage changes (MMPCs) using joinpoint regression analysis. For short‐acting β₂ agonist inhalers, we assumed that a mean 1.5 inhalers were dispensed per script; in a sensitivity analysis, we assumed a mean of one inhaler was dispensed per script (further details: Supporting Information, part 1). The University of Canberra human research ethics committee exempted the study from formal ethics review (HREC 2024/14042). Access to the data and approval for the publication of findings based on the data were granted by Services Australia as data custodian.

The number of PBS‐subsidised inhalers dispensed increased from 14.4 million in the 2019 calendar year to 15.5 million in 2023 (MMPC, 0.32%; 95% confidence interval [CI], 0.12–0.52%); estimated emissions increased from 217 510 t to 246 934 t CO₂e (MMPC, 0.46%; 95% CI, 0.22–0.71%). The increased dispensing of inhalers was primarily caused by the increased dispensing of high emissions inhalers, from 8.2 million to 9.2 million (MMPC, 0.43%; 95% CI, 0.22–0.65%); the dispensing of low emissions inhaler increased from 6.2 million to 6.3 million (MMPC, 0.15%; 95% CI, 0.01–0.29%). In 2019, 56.9% of dispensed PBS‐subsidised inhalers were high emission inhalers, and 59.5% in 2023; in each year, they accounted for about 98% of total estimated PBS‐subsidised inhaler‐related emissions (Box 1; Box 2). The sensitivity analysis yielded similar results (Supporting Information, table 2).

Estimated emissions were greatest for short‐acting β₂ agonist inhalers (4.8–5.5 million dispensed per year; 2023: 98% in high emissions inhalers; 140 558 t CO₂e, 57% of all inhaler‐related emissions) and combined inhaled corticosteroid/long‐acting β₂ agonist inhalers (5.6–6.4 million dispensed per year; 2023: 49% in high emissions inhalers; 83 491 t CO₂e, 34% of all inhaler‐related emissions) (Supporting Information, table 3 and figure 1).

PBS‐subsidised inhaler dispensing rates were higher in non‐metropolitan (2023: 704 per 1000 population) than in metropolitan areas (2023: 450 per 1000 population), but estimated total emissions were higher in metropolitan areas because of the larger numbers of inhalers dispensed (2023: metropolitan, 155 878 t CO₂e; non‐metropolitan: 91 010 t CO₂e). Estimated emissions increased in non‐metropolitan areas during 2019–2023 for both low emissions inhalers (MMPC, 0.29%; 95% CI, 0.17–0.41%) and high emissions inhalers (MMPC, 0.53%; 95% CI, 0.34–0.73%); in metropolitan areas, they increased for high emissions inhalers only (MMPC, 0.43%; 95% CI, 0.16–0.72%) (Supporting Information, table 3).

PBS‐subsidised inhaler dispensing rates were highest in Tasmania (2023: 693 per 1000 population) and South Australia (2023: 632 per 1000 population) and lowest in the Northern Territory (355 per 1000 population) and Western Australia (383 per 1000 population). The proportions of high emissions inhalers dispensed were largest in South Australia (63–65%) and the Northern Territory (59–64%) and smallest in the Australian Capital Territory (53–57%) and Western Australia (52–56%). Total estimated emissions were highest in New South Wales (2023: 78 500 t CO₂e) and Victoria (2023: 62 622 t CO₂e). Emissions increased in all states and territories between 2019 and 2023, primarily because of the increased dispensing of high emissions inhalers; MMPCs ranged from 0.31 (95% CI, 0.04–0.58%) in New South Wales to 0.64 (95% CI, 0.35–0.93%) in Victoria (Supporting Information, table 3).

In 2023, the PBS‐subsidised inhaler dispensing rate was 195 per 1000 people aged 0–19 years (high emissions inhalers, 92%) and 2054 per 1000 people aged 80 years or older (high emissions inhalers, 50%) (Box 3). The age group dispensed the largest proportion of PBS‐subsidised inhalers were people aged 60–79 years (6.4–7.1 million/year; 43–45% of all PBS‐subsidised inhalers dispensed; high emissions inhalers, 50–54%), contributing 100 688t CO₂e in 2023 (about 41% of all emissions). Increases in PBS‐subsidised high emissions inhaler dispensing rates (MMPC, 0.34%; 95% CI, 0.03–0.66%) and emissions (MMPC, 0.61%; 95% CI, 0.30–0.91%) were greatest for people aged 80 years or older. PBS‐subsidised dispensing numbers and rates were higher for female than male users (2023: 549 v 462 per 1000 population); the proportions of high emissions inhalers dispensed were larger for female than male users (58–60% v 55–58%), and the increase in high emissions inhaler‐related emissions was greater (MMPC, 0.50%; 95% CI, 0.23–0.78% v 0.44%; 95% CI, 0.19–0.69%) (Supporting Information, table 3).

Limitations to our study include the omission of over‐the‐counter sales from our detailed analysis, some missing data, and the use of United Kingdom data2 for emission estimates. Based on the findings of another study,4 we estimate that total emissions from both over‐the‐counter short‐acting β₂ agonist inhalers and all dispensed PBS‐subsidised prescription inhalers in Australia in 2019 were 437 867 t CO₂e, or 17.3 kg CO₂e per person (details: Supporting Information, part 1). In Great Britain, 61.1 million inhalers contributed 20.4 kg CO₂e per person in 2021,5 in Sweden 4.8 million inhalers (in 2017)6 contributed 2.5 kg CO₂e emissions per person per year (in 2018–19).7

In the first comprehensive estimate of carbon emissions for PBS‐subsidised inhalers in Australia, we found differences in dispensing according to the demographic characteristics of inhaler users. To better support efforts to reduce respiratory inhaler emissions as part of Australian health care decarbonisation plans,1 we recommend routine collecting and reporting of over‐the‐counter inhaler sales data, and that these data are made freely available to complement PBS‐subsidised dispensing data. Our findings could inform targeted interventions for reducing the use of high emission inhalers in Australia and updates to clinical practice guidelines.

Box 2 – Pharmaceutical Benefits Scheme (PBS)‐subsidised dispensing of respiratory inhalers and estimated carbon emissions, Australia, 2019–2023, by inhaler type and month*

---

CO₂e = carbon dioxide equivalent.* Solid line: raw data; dotted line: linear trend, 2019–2023; dashed line (March 2020: coronavirus disease 2019‐related divergence from normal dispensing): unadjusted raw data that were replaced by mean of values for March 2019 and March 2021.